Multivariable regression models for distinct patient subsets
| . | Risk of relapse . | Risk of relapse/death . | Risk of death . | Risk of NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Patients with AML and MDS/AML not receiving any post-HCT maintenance therapy (n = 866) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 2.99 (2.08-4.28) | <.001 | 1.93 (1.45-2.56) | <.001 | 1.79 (1.34-3.90) | <.001 | 1.08 (0.66-1.77) | .75 |
| MRDpos/MRDpos | 5.20 (1.82-14.90) | <.001 | 4.60 (2.05-10.31) | <.001 | 5.44 (2.41-12.28) | <.001 | 5.09 (1.45-17.85) | .011 |
| Patients with AML only (n = 851) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 3.34 (2.32-4.81) | <.001 | 2.15 (1.61-2.89) | <.001 | 2.04 (1.49-2.79) | <.001 | 1.11 (0.65-1.92) | .70 |
| MRDpos/MRDpos | 6.45 (2.51-16.58) | <.001 | 5.26 (2.47-11.18) | <.001 | 5.96 (3.22-11.18) | <.001 | 5.14 (1.47-17.94) | .010 |
| Patients with AML and MDS/AML undergoing MAC (n = 569) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 3.81 (2.46-5.89) | <.001 | 2.31 (1.61-3.32) | <.001 | 2.09 (1.43-3.07) | <.001 | 1.16 (0.42-1.79) | .70 |
| MRDpos/MRDpos | 5.77 (1.63-20.38) | .005 | 6.39 (2.56-15.91) | <.001 | 6.50 (2.41-17.51) | <.001 | 9.41 (2.57-34.49) | <.001 |
| Patients with AML and MDS/AML undergoing non-MAC (n = 366) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 2.16 (1.13-4.12) | .020 | 1.55 (0.98-2.46) | .062 | 1.32 (0.82-2.12) | .25 | 1.15 (0.60-2.23) | 0.38 |
| MRDpos/MRDpos | 7.44 (1.97-28.13) | .003 | 5.90 (1.74-20.06) | .004 | 7.14 (2.11-24.16) | .002 | Too few N to estimate- | - |
| Patients with AML and MDS/AML receiving 10/10 HLA-identical/matched related or unrelated donor allograft (n = 685) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 2.56 (1.66-3.93) | <.001 | 1.78 (1.27-2.50) | <.001 | 1.57 (1.11-2.24) | .011 | 1.03 (0.58-1.83) | .91 |
| MRDpos/MRDpos | 8.08 (3.35-19.51) | <.001 | 5.33 (2.48-11.50) | <.001 | 5.01 (2.22-11.34) | <.001 | 2.71 (0.59-12.51) | .20 |
| Patients with AML and MDS/AML with sufficient cytogenetic/molecular data for ELN 2022 risk classification (n = 521) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 2.75 (1.70-4.45) | <.001 | 2.01 (1.34-3.01) | .001 | 1.73 (1.12-2.67) | .013 | 0.98 (0.43-2.21) | .96 |
| MRDpos/MRDpos | 4.42 (1.28-15.20) | <.001 | 2.98 (1.02-8.66) | .045 | 3.44 (1.18-10.01) | .024 | 1.79 (0.21-14.87) | .59 |
| . | Risk of relapse . | Risk of relapse/death . | Risk of death . | Risk of NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Patients with AML and MDS/AML not receiving any post-HCT maintenance therapy (n = 866) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 2.99 (2.08-4.28) | <.001 | 1.93 (1.45-2.56) | <.001 | 1.79 (1.34-3.90) | <.001 | 1.08 (0.66-1.77) | .75 |
| MRDpos/MRDpos | 5.20 (1.82-14.90) | <.001 | 4.60 (2.05-10.31) | <.001 | 5.44 (2.41-12.28) | <.001 | 5.09 (1.45-17.85) | .011 |
| Patients with AML only (n = 851) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 3.34 (2.32-4.81) | <.001 | 2.15 (1.61-2.89) | <.001 | 2.04 (1.49-2.79) | <.001 | 1.11 (0.65-1.92) | .70 |
| MRDpos/MRDpos | 6.45 (2.51-16.58) | <.001 | 5.26 (2.47-11.18) | <.001 | 5.96 (3.22-11.18) | <.001 | 5.14 (1.47-17.94) | .010 |
| Patients with AML and MDS/AML undergoing MAC (n = 569) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 3.81 (2.46-5.89) | <.001 | 2.31 (1.61-3.32) | <.001 | 2.09 (1.43-3.07) | <.001 | 1.16 (0.42-1.79) | .70 |
| MRDpos/MRDpos | 5.77 (1.63-20.38) | .005 | 6.39 (2.56-15.91) | <.001 | 6.50 (2.41-17.51) | <.001 | 9.41 (2.57-34.49) | <.001 |
| Patients with AML and MDS/AML undergoing non-MAC (n = 366) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 2.16 (1.13-4.12) | .020 | 1.55 (0.98-2.46) | .062 | 1.32 (0.82-2.12) | .25 | 1.15 (0.60-2.23) | 0.38 |
| MRDpos/MRDpos | 7.44 (1.97-28.13) | .003 | 5.90 (1.74-20.06) | .004 | 7.14 (2.11-24.16) | .002 | Too few N to estimate- | - |
| Patients with AML and MDS/AML receiving 10/10 HLA-identical/matched related or unrelated donor allograft (n = 685) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 2.56 (1.66-3.93) | <.001 | 1.78 (1.27-2.50) | <.001 | 1.57 (1.11-2.24) | .011 | 1.03 (0.58-1.83) | .91 |
| MRDpos/MRDpos | 8.08 (3.35-19.51) | <.001 | 5.33 (2.48-11.50) | <.001 | 5.01 (2.22-11.34) | <.001 | 2.71 (0.59-12.51) | .20 |
| Patients with AML and MDS/AML with sufficient cytogenetic/molecular data for ELN 2022 risk classification (n = 521) | ||||||||
| Pre-HCT/day +70 to +100 MRD dynamics | ||||||||
| MRDneg/MRDneg | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos/MRDneg | 2.75 (1.70-4.45) | <.001 | 2.01 (1.34-3.01) | .001 | 1.73 (1.12-2.67) | .013 | 0.98 (0.43-2.21) | .96 |
| MRDpos/MRDpos | 4.42 (1.28-15.20) | <.001 | 2.98 (1.02-8.66) | .045 | 3.44 (1.18-10.01) | .024 | 1.79 (0.21-14.87) | .59 |